Article information
Abstract
Objective
Due to the amount and variability in quality regarding the use of biologic therapy (BT) in patients with spondyloarthritis (SpA), except for psoriatic arthritis (PsA) patients, the Spanish Society of Rheumatology has promoted the generation of recommendations based on the best evidence available. These recommendations should be a reference for rheumatologists and those involved in the treatment of patients with spondyloarthritis (SpA), except for psoriatic arthritis (PsA), who are using, or about to use BT.
MethodsRecommendations were developed following a nominal group methodology and based on systematic reviews. The level of evidence and grade of recommendation were classified according to the model proposed by the Center for Evidence Based Medicine at Oxford. The level of agreement was established through Delphi technique.
ResultsWe have produced recommendations on the use of BT currently available for SpA (but not PsA) in our country. These recommendations include disease assessment, treatment objectives, therapeutic scheme and switching.
ConclusionsWe present an update on the SER recommendations for the use of BT in patients with SpA, except for PsA.
Keywords:
Consensus
Recommendations
Guide
Biologic therapy
Spondyloarthritis
Resumen
Objetivo
Dada la gran cantidad de información sobre las terapias biológicas (TB) en las espondiloartritis (EspA), excepto la artritis psoriásica (APs), y la variabilidad en cuanto a su calidad, desde la Sociedad Española de Reumatología (SER) se ha impulsado la generación de recomendaciones basadas en la mejor evidencia posible. Estas deben servir de referencia para reumatólogos e implicados en el tratamiento de estos pacientes.
MétodosLas recomendaciones se emitieron siguiendo la metodología de grupos nominales. El nivel de evidencia y el grado de recomendación se clasificaron según el modelo del Center for Evidence Based Medicine de Oxford y el grado de acuerdo se extrajo por técnica Delphi.
ResultadosSe realizan recomendaciones sobre el uso de las TB para el tratamiento de las EspA (excepto la APs). Incluyen la evaluación de la enfermedad, objetivos del tratamiento, esquema terapéutico y cambios en éste.
ConclusionesSe presentan las actualizaciones a las recomendaciones SER para el uso de TB en pacientes con EsA, excepto la APs.
Palabras clave:
Consenso
Recomendaciones
Guía
Terapia biológica
Full text is only aviable in PDF
References
[1.]
S. Van der Linden, H.A. Valkenburg, A. Cats.
Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria.
Arthritis Rheum., 27 (1984), pp. 361-368
[2.]
J. Braun, G. Kingsley, D. Van der Heijde, J. Sieper.
On the difficulties of establishing a consensus on the definition of and diagnostic investigations for reactive arthritis. Results and discussion of a questionnaire prepared for the 4th International Workshop on Reactive Arthritis, Berlin, Germany, July 3-6, 1999.
J Rheumatol., 27 (2000), pp. 2185-2192
[3.]
W. Taylor, D. Gladman, P. Helliwell, A. Marchesoni, P. Mease, H. Mielants.
Classification criteria for psoriatic arthritis: development of new criteria from a large international study.
Arthritis Rheum., 54 (2006), pp. 2665-2673
[4.]
M. Dougados, S. Van der Linden, R. Juhlin, B. Huitfeldt, B. Amor, A. Calin, et al.
The European Spondylarthropathy Study Gro*up preliminary criteria for the classification of spondylarthropathy.
Arthritis Rheum., 34 (1991), pp. 1218-1227
[5.]
B. Amor, M. Dougados, M. Mijiyawa.
Criteria of the classification of spondylarthropathies.
Rev Rhum Mal Osteoartic., 57 (1990), pp. 85-89
[6.]
J. Braun, T. Pincus.
Mortality, course of disease and prognosis of patients with ankylosing spondylitis.
Clin Exp Rheumatol., 20 (2002), pp. S16-S22
[7.]
M. Rudwaleit, M.A. Khan, J. Sieper.
The challenge of diagnosis and classification in early ankylosing spondylitis: do we need new criteria?.
Arthritis Rheum, 52 (2005), pp. 1000-1008
[8.]
J. Sieper, D. Van der Heijde, R. Landewe, J. Brandt, R. Burgos-Vagas, E. Collantes-Estevez, et al.
New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS).
Ann Rheum Dis., 68 (2009), pp. 784-788
[9.]
M. Rudwaleit, R. Landewe, D. Van der Heijde, J. Listing, J. Brandt, J. Braun, et al.
The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal.
Ann Rheum Dis., 68 (2009), pp. 770-776
[10.]
M. Rudwaleit, D. Van der Heijde, R. Landewé.
New ASAS classification criteria for peripheral spondyloarthritis.
Ann Rheum Dis., (2009),
[11.]
M. Rudwaleit, H. Haibel, X. Baraliakos, J. Listing, E. Marker-Hermann, H. Zeidler, et al.
The early disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception Cohort.
Arthritis Rheum., 60 (2009), pp. 717-727
[12.]
J. Braun, J. Sieper.
Ankylosing spondylitis.
Lancet., 369 (2007), pp. 1379-1390
[13.]
J. Braun, M. Bollow, G. Remlinger, U. Eggens, M. Rudwaleit, A. Distler, et al.
Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors.
Arthritis Rheum., 41 (1998), pp. 58-67
[14.]
J.T. Gran, G. Husby.
The epidemiology of ankylosing spondylitis.
Semin Arthritis Rheum., 22 (1993), pp. 319-334
[15.]
Munoz-Fernandez S, De Miguel E, Cobo-Ibanez T, Carmona L, Steiner M, Descalzo MA, et al. The incidence of early spondyloarthritis: results from the pilot registry ESPIDEP Clin Exp Rheumatol. 2010.
[16.]
E. Muñoz Gomariz, A. Cisnal del Mazo, E. Collantes Estevez.
Validación de criterios diagnósticos y de clasificación de las espondiloartropatías: Estudio multicéntrico en España.
Rev Esp Reumatol., 21 (1994), pp. 426-429
[17.]
M. Rojas-Vargas, E. Munoz-Gomariz, A. Escudero, P. Font, P. Zarco, R. Almodovar, et al.
First signs and symptoms of spondyloarthritis –data from an inception cohort with a disease course of two years or less (REGISPONSER-Early).
Rheumatology (Oxford)., 48 (2009), pp. 404-409
[18.]
F. Guillemin, S. Briancon, J. Pourel, A. Gaucher.
Long-term disability and prolonged sick leaves as outcome measurements in ankylosing spondylitis. Possible predictive factors.
Arthritis Rheum., 33 (1990), pp. 1001-1006
[19.]
R. Ariza-Ariza, B. Hernandez-Cruz, E. Collantes, E. Batlle, J.L. Fernandez-Sueiro, J. Gratacos, et al.
Work disability in patients with ankylosing spondylitis.
J Rheumatol., 36 (2009), pp. 2512-2516
[20.]
D. Van der Heijde, W.P. Maksymowych.
Spondyloarthritis: state of the art and future perspectives.
Ann Rheum Dis., 69 (2010), pp. 949-954
[21.]
Grupo ESPOGUIA.
Fármacos modificadores de la enfermedad.
Madrid: SER, (2010),
[22.]
D.O. Clegg, D.J. Reda, M. Abdellatif.
Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study.
Arthritis Rheum., 42 (1999), pp. 2325-2329
[23.]
A. Wanders, D. Heijde, R. Landewe, J.M. Behier, A. Calin, I. Olivieri, et al.
Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial.
Arthritis Rheum., 52 (2005), pp. 1756-1765
[24.]
K. Fitch, S.J. Bernstein, M.D. Aguilar, B. Burnand, J.R. LaCalle, P. Lazaro, et al.
The RAND/UCLA Appropriateness Method User's Manual.
Santa Monica: RAND, (2001),
[25.]
Sociedad Española de Reumatología. Guía de práctica clínica sobre el manejo de los pacientes con espondiloartritis (ESPOGUIA) 2010.
[26.]
E. Collantes, J.L. Fernández Sueiro, R. García-Vicuña, J. Gratacós, J. Mulero, S. Muñoz Fernández, et al.
Documento de consenso: Actualización del Consenso de la Sociedad Española de Reumatología sobre el uso de antagonistas del TNF en las espondiloartritis, incluida la artritis psoriásica.
Reumatol Clin., 3 (2007), pp. 60-70
[27.]
CEBM CfEBM Oxford Centre for Evidence-based Medicine−Levels of Evidence (March 2009). 2009.
[28.]
J. Brandt, H. Haibel, J. Reddig, J. Sieper, J. Braun.
Successful short term treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor-alpha monoclonal antibody infliximab.
J Rheumatol., 29 (2002), pp. 118-122
[29.]
J. Braun, J. Brandt, J. Listing, A. Zink, R. Alten, W. Golder, et al.
Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial.
Lancet., 359 (2002), pp. 1187-1193
[30.]
A. Calin, B.A. Dijkmans, P. Emery, M. Hakala, J. Kalden, M. Leirisalo-Repo, et al.
Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis.
Ann Rheum Dis., 63 (2004), pp. 1594-1600
[31.]
M.S. Heiberg, B.Y. Nordvag, K. Mikkelsen, E. Rodevand, C. Kaufmann, P. Mowinckel, et al.
The comparative effectiveness of tumor necrosis factor-blocking agents in patients with rheumatoid arthritis and patients with ankylosing spondylitis: a six-month, longitudinal, observational, multicenter study.
Arthritis Rheum., 52 (2005), pp. 2506-2512
[32.]
D. Van der Heijde, A. Kivitz, M.H. Schiff, J. Sieper, B.A. Dijkmans, J. Braun, et al.
Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial.
Arthritis Rheum., 54 (2006), pp. 2136-2146
[33.]
D.A. Revicki, M.P. Luo, P. Wordsworth, R.L. Wong, N. Chen, J.C. Davis.
Adalimumab reduces pain, fatigue, and stiffness in patients with ankylosing spondylitis: results from the adalimumab trial evaluating long-term safety and efficacy for ankylosing spondylitis (ATLAS).
J Rheumatol., 35 (2008), pp. 1346-1353
[34.]
L. Carmona, J.J. Gomez-Reino.
Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis.
Data from the Spanish registry BIOBADASER Arthritis Res Ther., 8 (2006), pp. R72
[35.]
A.I. Venetsanopoulou, P.V. Voulgari, Y. Alamanos, C.G. Papadopoulos, T.E. Markatseli, A.A. Drosos.
Persistent clinical response of infliximab treatment, over a 4-year period in ankylosing spondylitis.
Rheumatol Int., 27 (2007), pp. 935-939
[36.]
D. Van der Heijde, A.L. Pangan, M.H. Schiff, J. Braun, M. Borofsky, J. Torre, et al.
Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis.
Ann Rheum Dis., 67 (2008), pp. 1218-1221
[37.]
M. Rudwaleit, I. Olivieri, K.A. Boki, E.N. Griep, P. Jarvinen, R.L. Wong, et al.
Adalimumab is effective and well tolerated in treating patients with ankylosing spondylitis who have advanced spinal fusion.
Rheumatology (Oxford)., 48 (2009), pp. 551-557
[38.]
X. Baraliakos, J. Listing, J. Brandt, A. Zink, R. Alten, G. Burmester, et al.
Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab.
Arthritis Res Ther., 7 (2005), pp. R439-R444
[39.]
H. Haibel, M. Rudwaleit, J. Listing, F. Heldmann, R.L. Wong, H. Kupper, et al.
Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two.
Arthritis Rheum., 58 (2008), pp. 1981-1991
[40.]
M. Rudwaleit, P. Claudepierre, P. Wordsworth, E.L. Cortina, J. Sieper, M. Kron, et al.
Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis.
J Rheumatol., 36 (2009), pp. 801-808
[41.]
D. Van der Heijde, R. Landewe, X. Baraliakos, H. Houben, A. Van Tubergen, P. Williamson, et al.
Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis.
Arthritis Rheum., 58 (2008), pp. 3063-3070
[42.]
D. Van der Heijde, R. Landewe, S. Einstein, P. Ory, D. Vosse, L. Ni, et al.
Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept.
Arthritis Rheum., 58 (2008), pp. 1324-1331
[43.]
D. Van der Heijde, D. Salonen, B.N. Weissman, R. Landewe, W.P. Maksymowych, H. Kupper, et al.
Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years.
Arthritis Res Ther., 11 (2009), pp. R127
[44.]
J. Braun, X. Baraliakos, J. Listing, J. Sieper.
Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept.
Arthritis Rheum., 52 (2005), pp. 2447-2451
[45.]
A. Fernandez-Nebro, E. Tomero, V. Ortiz-Santamaria, M.C. Castro, A. Olive, M. De Haro, et al.
Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists.
Am J Med., 118 (2005), pp. 552-556
[46.]
G.K. Hatemi, I. Tascilar.
Tumor necrosis factor alpha antagonists in the treatment of secondary amiloidosis.
Arthritis Rheum., 58 (2008), pp. S475
[47.]
B.W. Behm, S.J. Bickston.
Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
Cochrane Database Syst Rev, (2008),
[48.]
M.M. Lawson, A.G. Thomas, A.K. Akobeng.
Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis.
Cochrane Database Syst Rev., 3 (2006),
[49.]
U. Lange, J. Teichmann, U. Muller-Ladner, J. Strunk.
Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-alpha antibody: a prospective open-label pilot study.
Rheumatology (Oxford)., 44 (2005), pp. 1546-1548
[50.]
S. Mathieu, J.J. Dubost, A. Tournadre, S. Malochet-Guinamand, J.M. Ristori, M. Soubrier.
Effects of 14 weeks of TNF alpha blockade treatment on lipid profile in ankylosing spondylitis.
Joint Bone Spine., 77 (2010), pp. 50-52
[51.]
J. Brandt, A. Khariouzov, J. Listing, H. Haibel, H. Sorensen, L. Grassnickel, et al.
Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis.
Arthritis Rheum., 48 (2003), pp. 1667-1675
[52.]
X. Baraliakos, J. Listing, M. Rudwaleit, J. Brandt, R. Alten, G. Burmester, et al.
Safety and efficacy of readministration of infliximab after longterm continuous therapy and withdrawal in patients with ankylosing spondylitis.
J Rheumatol., 34 (2007), pp. 510-515
[53.]
J. Brandt, J. Listing, H. Haibel, H. Sorensen, A. Schwebig, M. Rudwaleit, et al.
Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis.
Rheumatology (Oxford)., 44 (2005), pp. 342-348
[54.]
A. Galor, V.L. Perez, J.P. Hammel, C.Y. Lowder.
Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation.
Ophthalmology., 113 (2006), pp. 2317-2323
[55.]
C. Delaunay, V. Farrenq, A. Marini-Portugal, J.D. Cohen, X. Chevalier, P. Claudepierre.
Infliximab to etanercept switch in patients with spondyloarthropathies and psoriatic arthritis: preliminary data.
J Rheumatol., 32 (2005), pp. 2183-2185
[56.]
D. Van der Heijde, J.C. Da Silva, M. Dougados, P. Geher, I. Van der Horst-Bruinsma, X. Juanola, et al.
Etanercept 50mg once weekly is as effective as 25mg twice weekly in patients with ankylosing spondylitis.
Ann Rheum Dis., 65 (2006), pp. 1572-1577
[57.]
J.D. Gorman, K.E. Sack, J.C. Davis.
Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha.
N Engl J Med., 346 (2002), pp. 1349-1356
[58.]
J.C. Davis, D. Van Der Heijde, J. Braun, M. Dougados, J. Cush, D.O. Clegg, et al.
Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial.
Arthritis Rheum., 48 (2003), pp. 3230-3236
[59.]
R.J. Meador, E.C. Hsia, T. Kitumnuaypong, H.R. Schumacher.
Is etanercept (Enbrel) effective in the treatment of reactive and undifferentiated arthritis?.
Arthritis Rheum., 44 (2001), pp. S348
[60.]
S.D. Flagg, R. Meador, E. Hsia, T. Kitumnuaypong, H.R. Schumacher.
Decreased pain and synovial inflammation after etanercept therapy in patients with reactive and undifferentiated arthritis: an open-label trial.
Arthritis Rheum., 53 (2005), pp. 613-617
[61.]
A. Boonen, V. Patel, S. Traina, C.F. Chiou, A. Maetzel, W. Tsuji.
Rapid and sustained improvement in health-related quality of life and utility for 72 weeks in patients with ankylosing spondylitis receiving etanercept.
J Rheumatol., 35 (2008), pp. 662-667
[62.]
X. Baraliakos, J. Davis, W. Tsuji, J. Braun.
Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor alpha receptor fusion protein etanercept.
Arthritis Rheum., 52 (2005), pp. 1216-1223
[63.]
M. Rudwaleit, X. Baraliakos, J. Listing, J. Brandt, J. Sieper, J. Braun.
Magnetic resonance imaging of the spine and the sacroiliac joints in ankylosing spondylitis and undifferentiated spondyloarthritis during treatment with etanercept.
Ann Rheum Dis., 64 (2005), pp. 1305-1310
[64.]
M.K. De Vries, I.E. Van der Horst-Bruinsma, M.T. Nurmohamed, L.A. Aarden, S.O. Stapel, M.J. Peters, et al.
Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis.
Ann Rheum Dis., 68 (2009), pp. 531-535
[65.]
W.P. Maksymowych, A.R. Poole, L. Hiebert, A. Webb, M. Ionescu, T. Lobanok, et al.
Etanercept exerts beneficial effects on articular cartilage biomarkers of degradation and turnover in patients with ankylosing spondylitis.
J Rheumatol., 32 (2005), pp. 1911-1917
[66.]
J.H. Woo, H.J. Lee, I.H. Sung, T.H. Kim.
Changes of clinical response and bone biochemical markers in patients with ankylosing spondylitis taking etanercept.
J Rheumatol., 34 (2007), pp. 1753-1759
[67.]
N. Barkham, L.C. Coates, H. Keen, E. Hensor, A. Fraser, A. Redmond, et al.
Doubleblind placebo-controlled trial of etanercept in the prevention of work disability in ankylosing spondylitis.
Ann Rheum Dis., (2010),
[68.]
I.C. Van Eijk, M.J. Peters, E.H. Serne, I.E. Van der Horst-Bruinsma, B.A. Dijkmans, Y.M. Smulders, et al.
Microvascular function is impaired in ankylosing spondylitis and improves after tumour necrosis factor alpha blockade.
Ann Rheum Dis., 68 (2009), pp. 362-366
[69.]
J. Sieper, A. Koenig, S. Baumgartner, C. Wishneski, J. Foehl, B. Vlahos, et al.
Analysis of uveitis rates across all etanercept ankylosing spondylitis clinical trials.
Ann Rheum Dis., 69 (2010), pp. 226-229
[70.]
J.C. Davis, D.M. Van der Heijde, J. Braun, M. Dougados, D.O. Clegg, A.J. Kivitz, et al.
Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis.
Ann Rheum Dis., 67 (2008), pp. 346-352
[71.]
X. Baraliakos, J. Brandt, J. Listing, H. Haibel, H. Sorensen, M. Rudwaleit, et al.
Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data.
Arthritis Rheum., 53 (2005), pp. 856-863
[72.]
E. Martin-Mola, J. Sieper, M. Leirisalo-Repo, B.A. Dijkmans, B. Vlahos, R. Pedersen, et al.
Sustained efficacy and safety, including patient-reported outcomes, with etanercept treatment over 5 years in patients with ankylosing spondylitis.
Clin Exp Rheumatol., 28 (2010), pp. 238-245
[73.]
W.P. Maksymowych, G.S. Jhangri, R.G. Lambert, C. Mallon, H. Buenviaje, E. Pedrycz, et al.
Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety.
J Rheumatol., 29 (2002), pp. 959-965
[74.]
S. Keeling, A. Oswald, A.S. Russell, W.P. Maksymowych.
Prospective observational analysis of the efficacy and safety of low-dose (3 mg/kg) infliximab in ankylosing spondylitis: 4-year followup.
J Rheumatol., 33 (2006), pp. 558-561
[75.]
M.A. D’Agostino, M. Breban, R. Said-Nahal, M. Dougados.
Refractory inflammatory heel pain in spondylarthropathy: a significant response to infliximab documented by ultrasound.
Arthritis Rheum., 46 (2002), pp. 840-841
[76.]
N. Gaylis.
Infliximab in the treatment of an HIV positive patient with Reiter's syndrome.
J Rheumatol., 30 (2003), pp. 407-411
[77.]
M.D. Schafranski.
Infliximab for reactive arthritis secondary to Chlamydia trachomatis infection.
Rheumatol Int., 30 (2010), pp. 679-680
[78.]
F. Van den Bosch, E. Kruithof, D. Baeten, F. De Keyser, H. Mielants, E.M. Veys.
Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study.
Ann Rheum Dis., 59 (2000), pp. 428-433
[79.]
F. Van Den Bosch, E. Kruithof, D. Baeten, A. Herssens, F. De Keyser, H. Mielants, et al.
Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy.
Arthritis Rheum., 46 (2002), pp. 755-765
[80.]
J. Braun, X. Baraliakos, W. Golder, J. Brandt, M. Rudwaleit, J. Listing, et al.
Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system.
Arthritis Rheum., 48 (2003), pp. 1126-1136
[81.]
N. Barkham, H.I. Keen, L.C. Coates, P. O’Connor, E. Hensor, A.D. Fraser, et al.
Clinical and imaging efficacy of infliximab in HLA-B27-Positive patients with magnetic resonance imaging-determined early sacroiliitis.
Arthritis Rheum., 60 (2009), pp. 946-954
[82.]
H. Marzo-Ortega, D. McGonagle, S. Jarrett, G. Haugeberg, E. Hensor, P. O’Connor, et al.
Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study.
Ann Rheum Dis., 64 (2005), pp. 1568-1575
[83.]
D. Van der Heijde, C. Han, K. DeVlam, G. Burmester, F. Van den Bosch, P. Williamson, et al.
Infliximab improves productivity and reduces workday loss in patients with ankylosing spondylitis: results from a randomized, placebo-controlled trial.
Arthritis Rheum., 55 (2006), pp. 569-574
[84.]
S. Visvanathan, D. Van der Heijde, A. Deodhar, C. Wagner, D.G. Baker, J. Han, et al.
Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis.
Ann Rheum Dis., 68 (2009), pp. 175-182
[85.]
D.N. Kiortsis, A.K. Mavridis, T.D. Filippatos, S. Vasakos, S.N. Nikas, A.A. Drosos.
Effects of infliximab treatment on lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis.
J Rheumatol., 33 (2006), pp. 921-923
[86.]
E. Kruithof, P. Kestelyn, C. Elewaut, D. Elewaut, F. Van Den Bosch, H. Mielants, et al.
Successful use of infliximab in a patient with treatment resistant spondyloarthropathy related uveitis.
Ann Rheum Dis., 61 (2002), pp. 470
[87.]
S. Guignard, L. Gossec, C. Salliot, A. Ruyssen-Witrand, M. Luc, M. Duclos, et al.
Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study.
Ann Rheum Dis., 65 (2006), pp. 1631-1634
[88.]
E.B. Suhler, J.R. Smith, M.S. Wertheim, A.K. Lauer, D.E. Kurz, T.D. Pickard, et al.
A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes.
Arch Ophthalmol., 123 (2005), pp. 903-912
[89.]
L. Sobrin, E.C. Kim, W. Christen, T. Papadaki, E. Letko, C.S. Foster.
Infliximab therapy for the treatment of refractory ocular inflammatory disease.
Arch Ophthalmol., 125 (2007), pp. 895-900
[90.]
T. Cobo, S. Muñoz-Fernández, V. Hidalgo, E. Martín-Mola.
Medium-long term treatment with infliximab and methotrexate in posterior and/or chronic uveitis refractory to conventional treatment.
Med Clin (Barc)., 126 (2006), pp. 34-35
[91.]
C.W. Teshima, A. Thompson, L. Dhanoa, L.A. Dieleman, R.N. Fedorak.
Long-term response rates to infliximab therapy for Crohn's disease in an outpatient cohort.
Can J Gastroenterol., 23 (2009), pp. 348-352
[92.]
J. Braun, J. Brandt, J. Listing, A. Zink, R. Alten, G. Burmester, et al.
Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis.
Ann Rheum Dis., 64 (2005), pp. 229-234
[93.]
M. Breban, P. Ravaud, P. Claudepierre, G. Baron, Y.D. Henry, C. Hudry, et al.
Maintenance of infliximab treatment in ankylosing spondylitis: results of a one-year randomized controlled trial comparing systematic versus ondemand treatment.
Arthritis Rheum., 58 (2008), pp. 88-97
[94.]
M. Rudwaleit, P. Claudepierre, M. Kron, S. Kary, R. Wong, H. Kupper.
Effectiveness of adalimumab in treating patients with ankylosing spondylitis associated with enthesitis and peripheral arthritis.
Arthritis Res Ther., 12 (2010), pp. R43
[95.]
J.C. Davis, D. Revicki, D.M. Van der Heijde, A.M. Rentz, R.L. Wong, H. Kupper, et al.
Health-related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: results from a randomized controlled study.
Arthritis Rheum., 57 (2007), pp. 1050-1057
[96.]
H. Bacquet-Deschryver, F. Jouen, M. Quillard, J.F. Menard, V. Goeb, T. Lequerre, et al.
Impact of three anti-TNFalpha biologics on existing and emergent autoimmunity in rheumatoid arthritis and spondylarthropathy patients.
J Clin Immunol., 28 (2008), pp. 445-455
[97.]
W.P. Maksymowych, K.L. Gooch, R.L. Wong, H. Kupper, D. Van der Heijde.
Impact of age, sex, physical function, health-related quality of life, and treatment with adalimumab on work status and work productivity of patients with ankylosing spondylitis.
J Rheumatol., 37 (2010), pp. 385-392
[98.]
D. Sanchez-Cano, J.L. Callejas-Rubio, N. Ortego-Centeno.
Use of adalimumab in poststreptococcal reactive arthritis.
J Clin Rheumatol., 13 (2007), pp. 176
[99.]
M. Rudwaleit, F. Van den Bosch, M. Kron, S. Kary, H. Kupper.
Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy.
Arthritis Res Ther., 12 (2010), pp. R117
[100.]
R.G. Lambert, D. Salonen, P. Rahman, R.D. Inman, R.L. Wong, S.G. Einstein, et al.
Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis: a multicenter, randomized, double-blind, placebo-controlled study.
Arthritis Rheum., 56 (2007), pp. 4005-4014
[101.]
W.P. Maksymowych, P. Rahman, K. Shojania, W.P. Olszynski, G.T. Thomson, S. Ballal, et al.
Beneficial effects of adalimumab on biomarkers reflecting structural damage in patients with ankylosing spondylitis.
J Rheumatol., 35 (2008), pp. 2030-2037
[102.]
M. Rudwaleit, E. Rodevand, P. Holck, J. Vanhoof, M. Kron, S. Kary, et al.
Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study.
Ann Rheum Dis., 68 (2009), pp. 696-701
[103.]
D.M. Van der Heijde, D.A. Revicki, K.L. Gooch, R.L. Wong, H. Kupper, N. Harnam, et al.
Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis.
Arthritis Res Ther., 11 (2009), pp. R124
[104.]
R.D. Inman, J.C. Davis, D. Heijde, L. Diekman, J. Sieper, S.I. Kim, et al.
Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial.
Arthritis Rheum., 58 (2008), pp. 3402-3412
[105.]
J. Braun, R. Inman, D. Van der Heijde, C. Mack, S. Parasuraman, J. Buchanan.
Golimumab significantly improves productivity in patients with active ankylosing spondylitis: Results from the phase 3 GO-RAISE study.
Arthritis Rheum., 58 (2008),
[106.]
A. Deodhar, J. Braun, R.D. Inman, M. Mack, S. Parasuraman, J. Buchanan, et al.
Golimumab reduces sleep disturbance in patients with active ankylosing spondylitis: results from a randomized, placebo-controlled trial.
Arthritis Care Res (Hoboken)., 62 (2010), pp. 1266-1271
[107.]
D. Van der Heijde, J. Braun, A. Deodhar, R. Inman, M. Mack.
Head to head comparison of three enthesitis indices in the ankylosing spondilytis anti- TNF-a trial of Golimumab (GO-RAISE).
Arthritis Rheum., 58 (2008), pp. S369
[108.]
D. Furst, M.K. Doyle, J. Kay, M.C. Wasko, L. Moreland, E. Keystone.
Golimumab, a new human anti-TNF-alpha monoclonal antibody administered subcutaneously every 4 weeks, improves anemia & well-being in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis.
Arthritis Rheum., 58 (2008),
[109.]
M. Rudwaleit.
New approaches to diagnosis and classification of axial and peripheral spondyloarthritis.
Curr Opin Rheumatol., 22 (2010), pp. 375-380
[110.]
D. Van der Heijde, H.S. Baraf, C. Ramos-Remus, A. Calin, A.L. Weaver, M. Schiff, et al.
Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study.
Arthritis Rheum., 52 (2005), pp. 1205-1215
[111.]
S.J. Jarrett, F. Sivera, L.S. Cawkwell, H. Marzo-Ortega, D. McGonagle, E. Hensor, et al.
MRI and clinical findings in patients with ankylosing spondylitis eligible for anti-tumour necrosis factor therapy after a short course of etoricoxib.
Ann Rheum Dis., 68 (2009), pp. 1466-1469
[112.]
C. Lukas, R. Landewe, J. Sieper, M. Dougados, J. Davis, J. Braun, et al.
Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis.
Ann Rheum Dis., 68 (2009), pp. 18-24
[113.]
D. Van der Heijde, E. Lie, T.K. Kvien, J. Sieper, F. Van den Bosch, J. Listing, et al.
ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis.
Ann Rheum Dis., 68 (2009), pp. 1811-1818
[114.]
S.J. Pedersen, I.J. Sorensen, K.G. Hermann, O.R. Madsen, N. Tvede, M.S. Hansen, et al.
Responsiveness of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumour necrosis factor alpha inhibitors.
Ann Rheum Dis., 69 (2010), pp. 1065-1071
[115.]
S. Garrett, T. Jenkinson, L.G. Kennedy, H. Whitelock, P. Gaisford, A. Calin.
A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index.
J Rheumatol., 21 (1994), pp. 2286-2291
[116.]
M.A. Stone, R.D. Inman, J.G. Wright, A. Maetzel.
Validation exercise of the Ankylosing Spondylitis Assessment Study (ASAS) group response criteria in ankylosing spondylitis patients treated with biologics.
Arthritis Rheum., 51 (2004), pp. 316-320
[117.]
A.J. Wanders, J.D. Gorman, J.C. Davis, R.B. Landewe, D.M. Van der Heijde.
Responsiveness and discriminative capacity of the assessments in ankylosing spondylitis disease-controlling antirheumatic therapy core set and other outcome measures in a trial of etanercept in ankylosing spondylitis.
Arthritis Rheum., 51 (2004), pp. 1-8
[118.]
J. Sieper, M. Rudwaleit, X. Baraliakos, J. Brandt, J. Braun, R. Burgos-Vargas, et al.
The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis.
Ann Rheum Dis., 68 (2009), pp. ii1-ii44
[119.]
A. Calin, S. Garrett, H. Whitelock, L.G. Kennedy, J. O’Hea, P. Mallorie, et al.
A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index.
J Rheumatol., 21 (1994), pp. 2281-2285
[120.]
J.J. Anderson, G. Baron, D. Van der Heijde, D.T. Felson, M. Dougados.
Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis.
Arthritis Rheum., 44 (2001), pp. 1876-1886
[121.]
J. Brandt, J. Listing, J. Sieper, M. Rudwaleit, D. Van der Heijde, J. Braun.
Development and preselection of criteria for short term improvement after anti-TNF alpha treatment in ankylosing spondylitis.
Ann Rheum Dis., 63 (2004), pp. 1438-1444
[122.]
M. Rudwaleit, D. Van der Heijde, M.A. Khan, J. Braun, J. Sieper.
How to diagnose axial spondyloarthritis early.
Ann Rheum Dis., 63 (2004), pp. 535-543
[123.]
A.N. Bennett, D. McGonagle, P. O’Connor, E.M. Hensor, F. Sivera, L.C. Coates, et al.
Severity of baseline magnetic resonance imaging-evident sacroiliitis and HLA-B27 status in early inflammatory back pain predict radiographically evident ankylosing spondylitis at eight years.
Arthritis Rheum., 58 (2008), pp. 3413-3418
[124.]
M. Rudwaleit, D. Van der Heijde, R. Landewe, J. Listing, N. Akkoc, J. Brandt, et al.
The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection.
Ann Rheum Dis., 68 (2009), pp. 777-783
[125.]
M. Rudwaleit, S. Schwarzlose, E.S. Hilgert, J. Listing, J. Braun, J. Sieper.
MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis.
Ann Rheum Dis., 67 (2008), pp. 1276-1281
[126.]
A.N. Bennett, A. Rehman, E.M. Hensor, H. Marzo-Ortega, P. Emery, D. McGonagle.
Evaluation of the diagnostic utility of spinal magnetic resonance imaging in axial spondylarthritis.
Arthritis Rheum., 60 (2009), pp. 1331-1341
[127.]
M. Rudwaleit, A.G. Jurik, K.G. Hermann, R. Landewe, D. Van der Heijde, X. Baraliakos, et al.
Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI group.
Ann Rheum Dis., 68 (2009), pp. 1520-1527
[128.]
P.V. Balint, D. Kane, H. Wilson, I.B. McInnes, R.D. Sturrock.
Ultrasonography of entheseal insertions in the lower limb in spondyloarthropathy.
Ann Rheum Dis., 61 (2002), pp. 905-910
[129.]
M.A. D’Agostino, R. Said-Nahal, C. Hacquard-Bouder, J.L. Brasseur, M. Dougados, M. Breban.
Assessment of peripheral enthesitis in the spondylarthropathies by ultrasonography combined with power Doppler: a cross-sectional study.
Arthritis Rheum., 48 (2003), pp. 523-533
[130.]
E. De Miguel, T. Cobo, S. Munoz-Fernandez, E. Naredo, J. Uson, J.C. Acebes, et al.
Validity of enthesis ultrasound assessment in spondyloarthropathy.
Ann Rheum Dis., 68 (2009), pp. 169-174
[131.]
E. Naredo, E. Batlle-Gualda, M.L. Garcia-Vivar, A.M. Garcia-Aparicio, J.L. Fernandez- Sueiro, M. Fernandez-Prada, et al.
Power Doppler ultrasonography assessment of entheses in spondyloarthropathies: response to therapy of entheseal abnormalities.
J Rheumatol., 37 (2010), pp. 2110-2117
[132.]
P. Machado, R. Landewe, E. Lie, T.K. Kvien, J. Braun, D. Baker, et al.
Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores.
Ann Rheum Dis., (2010),
[133.]
F. Conti, F. Ceccarelli, E. Marocchi, L. Magrini, F.R. Spinelli, A. Spadaro, et al.
Switching tumour necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period.
Ann Rheum Dis., 66 (2007), pp. 1393-1397
[134.]
R.D. Inman, W.P. Maksymowych.
A double-blind, placebo-controlled trial of low dose infliximab in ankylosing spondylitis.
J Rheumatol., 37 (2010), pp. 1203-1210
[135.]
R.N. Jois, J. Leeder, A. Gibb, K. Gaffney, A. Macgregor, M. Somerville, et al.
Lowdose infliximab treatment for ankylosing spondylitis−clinically- and cost-effective.
Rheumatology (Oxford)., 45 (2006), pp. 1566-1569
[136.]
Abad MA, Ortiz A, Loza E, Martínez López JA, Rosario MP, Carmona L. Eficacia de la suspensión de biológicos en la EA controlada. 2009.
[137.]
V. Torrente, J. Gratacos, X. Juanola, R. Sanmartí, D. Suarez, M. Moreno, et al.
Infliximab withdrawal in patients with spondyloarthritis who presented criteria of clinical disease remission.
An Open Study of Clinical Practise (REMINEA), ACR Scientific Meeting, (2009),
Copyright © 2011. Sociedad Española de Reumatología and Colegio Mexicano de Reumatología
